Sahsen Ventures — Full Portfolio
3 tracked investments · listed companies and verified rows first
Enzyme develops a Quality Management System (QMS) software platform for life science companies including drug, biologic, device, and digital product manufacturers, designed to streamline regulatory workflows and generate FDA-ready documentation.
Enterprise SoftwareHealthtechMedical DevicesSaaSSan Francisco, US
Jared Seehafer(Founder/CEO)inJacob Graham(Founder/Vice President QA/RA)in
Co-investorsY CombinatorAg Startup Engine SeedRefactor Capital
Parse.ly is a content analytics and audience intelligence platform offering a real-time dashboard, a content recommendation API, a data pipeline to warehouses, and AI-driven insights.
Data & InfrastructureMarketing TechMedia & Entertainment
Co-investorsHaatchHorizon Technology FinanceJanus Henderson InvestorsSARAS CAPITALSoleus Capital
Synthesize develops generative AI models that simulate human tissue responses to drugs and diseases for clinical trial design.
AI & Machine LearningBiotechDigital Health
Robert Bradley, PhDinJeff Leek, PhDinAlice Walsh, PhDinGregory Koytiger, PhDin
Co-investorsMadrona Venture GroupAI2 IncubatorInner Loop Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.